Figure 5. Antitumor properties of TTL-315 do not vary with host immunocompetency.
C57BL6/J syngeneic hosts (BL6) or immunodeficient nude mice (nu/nu) were injected s.c. with 1 × 105 B16F10 cells (day 0) and enrolled randomly in control or experimental cohorts (n = 10 all cohorts). On days 7, 10, 13 mice were administered by i.p. injection vehicle only or 40 mg/kg TTL-315 (0.1 ml total volume). Tumor volumes based on calculations from caliper measurements were determined with an endpoint of 24 days in the experiment. Data was evaluated by Student's T test.